WO2022134773A1 - 一种大环k-ras g12c抑制剂,其制备方法和用途 - Google Patents
一种大环k-ras g12c抑制剂,其制备方法和用途 Download PDFInfo
- Publication number
- WO2022134773A1 WO2022134773A1 PCT/CN2021/124469 CN2021124469W WO2022134773A1 WO 2022134773 A1 WO2022134773 A1 WO 2022134773A1 CN 2021124469 W CN2021124469 W CN 2021124469W WO 2022134773 A1 WO2022134773 A1 WO 2022134773A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- deuterium
- substituted
- membered
- cycloalkyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000003112 inhibitor Substances 0.000 title abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 129
- 201000011510 cancer Diseases 0.000 claims abstract description 81
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 claims abstract description 24
- 102200006538 rs121913530 Human genes 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000035772 mutation Effects 0.000 claims abstract description 14
- 230000001404 mediated effect Effects 0.000 claims abstract description 8
- 230000001919 adrenal effect Effects 0.000 claims abstract description 6
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 6
- 210000004072 lung Anatomy 0.000 claims abstract description 6
- 210000000653 nervous system Anatomy 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 297
- 229910052805 deuterium Inorganic materials 0.000 claims description 232
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 230
- 125000000623 heterocyclic group Chemical group 0.000 claims description 151
- 229910052736 halogen Inorganic materials 0.000 claims description 144
- 150000002367 halogens Chemical class 0.000 claims description 144
- -1 cyano, hydroxyl Chemical group 0.000 claims description 127
- 229910052739 hydrogen Inorganic materials 0.000 claims description 116
- 239000001257 hydrogen Substances 0.000 claims description 116
- 125000003545 alkoxy group Chemical group 0.000 claims description 111
- 150000002431 hydrogen Chemical class 0.000 claims description 84
- 125000003118 aryl group Chemical group 0.000 claims description 83
- 150000001875 compounds Chemical class 0.000 claims description 76
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 72
- 125000000304 alkynyl group Chemical group 0.000 claims description 72
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 72
- 229910020008 S(O) Inorganic materials 0.000 claims description 63
- 125000001424 substituent group Chemical group 0.000 claims description 55
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 45
- 125000001072 heteroaryl group Chemical group 0.000 claims description 42
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 39
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 39
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 36
- 229910052799 carbon Inorganic materials 0.000 claims description 36
- 230000036210 malignancy Effects 0.000 claims description 36
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 35
- 229910052801 chlorine Inorganic materials 0.000 claims description 35
- 239000000460 chlorine Substances 0.000 claims description 35
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 35
- 229910052731 fluorine Inorganic materials 0.000 claims description 35
- 239000011737 fluorine Substances 0.000 claims description 35
- 125000003342 alkenyl group Chemical group 0.000 claims description 34
- 125000004432 carbon atom Chemical group C* 0.000 claims description 34
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 33
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 33
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 31
- 125000004104 aryloxy group Chemical group 0.000 claims description 31
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 31
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 28
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 17
- 208000009956 adenocarcinoma Diseases 0.000 claims description 16
- 206010025323 Lymphomas Diseases 0.000 claims description 14
- 206010039491 Sarcoma Diseases 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 claims description 12
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 12
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 11
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 11
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 201000009030 Carcinoma Diseases 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 206010024612 Lipoma Diseases 0.000 claims description 8
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 8
- 206010016629 fibroma Diseases 0.000 claims description 8
- 201000011066 hemangioma Diseases 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000003566 oxetanyl group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 206010001233 Adenoma benign Diseases 0.000 claims description 6
- 206010043276 Teratoma Diseases 0.000 claims description 6
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 4
- 208000003200 Adenoma Diseases 0.000 claims description 4
- 201000003076 Angiosarcoma Diseases 0.000 claims description 4
- 206010006417 Bronchial carcinoma Diseases 0.000 claims description 4
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 4
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 4
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010027145 Melanocytic naevus Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 201000004404 Neurofibroma Diseases 0.000 claims description 4
- 208000007256 Nevus Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000008383 Wilms tumor Diseases 0.000 claims description 4
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 4
- 208000002458 carcinoid tumor Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 201000010260 leiomyoma Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 206010027191 meningioma Diseases 0.000 claims description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 4
- 201000008026 nephroblastoma Diseases 0.000 claims description 4
- 208000007538 neurilemmoma Diseases 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 4
- 206010039667 schwannoma Diseases 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 claims description 2
- 201000005262 Chondroma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 201000009047 Chordoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010048832 Colon adenoma Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000007659 Fibroadenoma Diseases 0.000 claims description 2
- 206010053717 Fibrous histiocytoma Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000007569 Giant Cell Tumors Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 201000005409 Gliomatosis cerebri Diseases 0.000 claims description 2
- 206010018404 Glucagonoma Diseases 0.000 claims description 2
- 206010018691 Granuloma Diseases 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims description 2
- 208000002927 Hamartoma Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 206010019629 Hepatic adenoma Diseases 0.000 claims description 2
- 206010073073 Hepatobiliary cancer Diseases 0.000 claims description 2
- 208000002260 Keloid Diseases 0.000 claims description 2
- 206010023330 Keloid scar Diseases 0.000 claims description 2
- 201000004462 Leydig Cell Tumor Diseases 0.000 claims description 2
- 208000002404 Liver Cell Adenoma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 208000000035 Osteochondroma Diseases 0.000 claims description 2
- 208000027067 Paget disease of bone Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 206010048214 Xanthoma Diseases 0.000 claims description 2
- 206010048215 Xanthomatosis Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 150000001345 alkine derivatives Chemical class 0.000 claims description 2
- 201000007434 ampulla of Vater carcinoma Diseases 0.000 claims description 2
- 208000001119 benign fibrous histiocytoma Diseases 0.000 claims description 2
- 208000016738 bone Paget disease Diseases 0.000 claims description 2
- 201000003149 breast fibroadenoma Diseases 0.000 claims description 2
- 208000011825 carcinoma of the ampulla of vater Diseases 0.000 claims description 2
- 201000005217 chondroblastoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims description 2
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 201000001343 fallopian tube carcinoma Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 201000007487 gallbladder carcinoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 2
- 201000000052 gastrinoma Diseases 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 208000006359 hepatoblastoma Diseases 0.000 claims description 2
- 201000002735 hepatocellular adenoma Diseases 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 208000023525 immature teratoma Diseases 0.000 claims description 2
- 206010022498 insulinoma Diseases 0.000 claims description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 2
- 210000001117 keloid Anatomy 0.000 claims description 2
- 208000003849 large cell carcinoma Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000004593 malignant giant cell tumor Diseases 0.000 claims description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 2
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims description 2
- 208000009091 myxoma Diseases 0.000 claims description 2
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 claims description 2
- 210000004498 neuroglial cell Anatomy 0.000 claims description 2
- 208000003388 osteoid osteoma Diseases 0.000 claims description 2
- 208000008798 osteoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- 210000000518 sarcolemma Anatomy 0.000 claims description 2
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims description 2
- 210000002536 stromal cell Anatomy 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 230000002381 testicular Effects 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 208000022271 tubular adenoma Diseases 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 201000002143 bronchus adenoma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 100
- 238000006243 chemical reaction Methods 0.000 description 75
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 52
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 42
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 42
- 239000002904 solvent Substances 0.000 description 40
- 238000003786 synthesis reaction Methods 0.000 description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- 230000015572 biosynthetic process Effects 0.000 description 32
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 23
- 125000005605 benzo group Chemical group 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 229940002612 prodrug Drugs 0.000 description 16
- 239000000651 prodrug Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 125000006413 ring segment Chemical group 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 125000003367 polycyclic group Chemical group 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 239000002994 raw material Substances 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 102000016914 ras Proteins Human genes 0.000 description 9
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 8
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 8
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108010014186 ras Proteins Proteins 0.000 description 6
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000010189 synthetic method Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- SKUSEKAIDHDZDY-UHFFFAOYSA-N CC(C)c1nccc(C=C)c1N Chemical compound CC(C)c1nccc(C=C)c1N SKUSEKAIDHDZDY-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 101150040459 RAS gene Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- BZXFKYRDEFEWPG-UHFFFAOYSA-N 2-bromo-4-chloropyridin-3-amine Chemical compound NC1=C(Cl)C=CN=C1Br BZXFKYRDEFEWPG-UHFFFAOYSA-N 0.000 description 3
- HNLNICWOZQXGGA-UHFFFAOYSA-N 4-chloro-2-propan-2-ylpyridin-3-amine Chemical compound CC(C)C1=NC=CC(Cl)=C1N HNLNICWOZQXGGA-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- TWHFNQXACTUQFD-UHFFFAOYSA-N ClC1=C(C(=NC=C1)C(=C)C)N Chemical compound ClC1=C(C(=NC=C1)C(=C)C)N TWHFNQXACTUQFD-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-Valine Natural products CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- LMAVIRPZHKSSNG-UHFFFAOYSA-N 7-chloro-1-(4-ethenyl-2-propan-2-ylpyridin-3-yl)-6-fluoropyrido[2,3-d]pyrimidine-2,4-dione Chemical compound CC(C)C1=NC=CC(C=C)=C1N(C(N=C(C(F)=C1)Cl)=C1C(N1)=O)C1=O LMAVIRPZHKSSNG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- FCDPQMAOJARMTG-UHFFFAOYSA-L benzylidene-[1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]-dichlororuthenium;tricyclohexylphosphane Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1.CC1=CC(C)=CC(C)=C1N(CCN1C=2C(=CC(C)=CC=2C)C)C1=[Ru](Cl)(Cl)=CC1=CC=CC=C1 FCDPQMAOJARMTG-UHFFFAOYSA-L 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XQSQTCCJLAMZBG-IBGZPJMESA-N tert-butyl (3S)-4-[1-(4-ethenyl-2-propan-2-ylpyridin-3-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C=C)=C1N(C(N=C(C(F)=C1)C(C(O)=CC=C2)=C2F)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O XQSQTCCJLAMZBG-IBGZPJMESA-N 0.000 description 2
- DDKJZXRLTFEFAP-INIZCTEOSA-N tert-butyl (3S)-4-[7-chloro-1-(4-ethenyl-2-propan-2-ylpyridin-3-yl)-6-fluoro-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C=C)=C1N(C(N=C(C(F)=C1)Cl)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O DDKJZXRLTFEFAP-INIZCTEOSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- FPXQHZPCFRQWCP-UHFFFAOYSA-N (2-fluoro-6-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=C(O)C=CC=C1F FPXQHZPCFRQWCP-UHFFFAOYSA-N 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- LVYJIIRJQDEGBR-UHFFFAOYSA-N 1-fluoro-2-iodoethane Chemical compound FCCI LVYJIIRJQDEGBR-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- ZVYNUGSPFZCYEV-UHFFFAOYSA-N 2,6-dichloro-5-fluoropyridine-3-carboxamide Chemical compound NC(=O)C1=CC(F)=C(Cl)N=C1Cl ZVYNUGSPFZCYEV-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- MCIPQLOKVXSHTD-UHFFFAOYSA-N 3,3-diethoxyprop-1-ene Chemical compound CCOC(C=C)OCC MCIPQLOKVXSHTD-UHFFFAOYSA-N 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- SVSUYEJKNSMKKW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-en-2-yl-1,3,2-dioxaborolane Chemical compound CC(=C)B1OC(C)(C)C(C)(C)O1 SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 1
- GTLFLMZOABSJSV-UHFFFAOYSA-N 4-chloropyridin-3-amine Chemical compound NC1=CN=CC=C1Cl GTLFLMZOABSJSV-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- WPQPZNDEYJDFEE-UHFFFAOYSA-N C(C1)CN1O[N]OC1OCC1 Chemical compound C(C1)CN1O[N]OC1OCC1 WPQPZNDEYJDFEE-UHFFFAOYSA-N 0.000 description 1
- XQWHPYZFUJOUMW-UHFFFAOYSA-N C1(CCCCC1)P(C1=C(C=CC=C1)C1=C(C=CC=C1OC)OC)C1CCCCC1.CS(=O)(=O)O Chemical group C1(CCCCC1)P(C1=C(C=CC=C1)C1=C(C=CC=C1OC)OC)C1CCCCC1.CS(=O)(=O)O XQWHPYZFUJOUMW-UHFFFAOYSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108010027920 GTPase-Activating Proteins Proteins 0.000 description 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- QWJZNHKZEPJRPZ-UHFFFAOYSA-N OC(=O)CC1CCCCCC1CC(O)=O Chemical compound OC(=O)CC1CCCCCC1CC(O)=O QWJZNHKZEPJRPZ-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- IFVTZJHWGZSXFD-UHFFFAOYSA-N biphenylene Chemical group C1=CC=C2C3=CC=CC=C3C2=C1 IFVTZJHWGZSXFD-UHFFFAOYSA-N 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- IAQRGUVFOMOMEM-ARJAWSKDSA-N cis-but-2-ene Chemical compound C\C=C/C IAQRGUVFOMOMEM-ARJAWSKDSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- ZKXWKVVCCTZOLD-UHFFFAOYSA-N copper;4-hydroxypent-3-en-2-one Chemical compound [Cu].CC(O)=CC(C)=O.CC(O)=CC(C)=O ZKXWKVVCCTZOLD-UHFFFAOYSA-N 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HGMZAXNHGAJOSO-UHFFFAOYSA-N cycloheptyl propanoate Chemical compound CCC(=O)OC1CCCCCC1 HGMZAXNHGAJOSO-UHFFFAOYSA-N 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- JMVOCSLPMGHXPG-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium Chemical compound [K+].[K+].[O-][Os]([O-])(=O)=O JMVOCSLPMGHXPG-UHFFFAOYSA-N 0.000 description 1
- DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 102200006532 rs112445441 Human genes 0.000 description 1
- 102200006531 rs121913529 Human genes 0.000 description 1
- 102200006539 rs121913529 Human genes 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- FMLPQHJYUZTHQS-QMMMGPOBSA-N tert-butyl (3s)-3-methylpiperazine-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-QMMMGPOBSA-N 0.000 description 1
- GCRNGPNGNJSZCC-UHFFFAOYSA-N tert-butyl 3-amino-3a,4,6,6a-tetrahydro-1h-pyrrolo[3,4-c]pyrazole-5-carboxylate Chemical compound N1N=C(N)C2CN(C(=O)OC(C)(C)C)CC21 GCRNGPNGNJSZCC-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical compound C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
- HJOAXCLZLHDZDX-UHFFFAOYSA-N tris(1,2,2-trifluoroethenyl) borate Chemical compound FC(F)=C(F)OB(OC(F)=C(F)F)OC(F)=C(F)F HJOAXCLZLHDZDX-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000004235 valence bond calculation Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention belongs to the field of drug synthesis, in particular to a macrocyclic K-RAS G12C inhibitor, a preparation method and uses thereof.
- the RAS gene family contains HRAS, KRAS and NRAS, which are frequently mutated in cancer as oncogenes. 20-30% of human tumors have mutated RAS proteins. Activated RAS proteins lead to malignant phenotypes of cancer cells, including dysregulation of cell growth and programmed cell death, increased invasiveness and neovascularization. Due to its high affinity for GTP/GDP and lack of a clear binding pocket, the development of drugs targeting RAS proteins has been slow.
- RAS proteins function as molecular switches, alternating between a GDP-bound inactive state and a GTP-bound activated state.
- RAS protein After stimulation by exogenous growth factors, RAS protein is converted from an inactive GDP-binding form to an activated GTP-binding form through the promotion of guanine nucleotide exchange factors (GEFs), which can bind and activate downstream signaling pathways.
- GEFs guanine nucleotide exchange factors
- GAP GTPase activating/accelerating protein
- K-RAS is the most frequently mutated subtype in the RAS family in human cancers, including pancreatic cancer (71%), small bowel cancer (35%), colon cancer (35%), biliary tract cancer (26%), and endometrial cancer (17%) and lung cancer (19%).
- pancreatic cancer 71%
- small bowel cancer 35%
- colon cancer 35%
- biliary tract cancer 26%
- endometrial cancer 17%)
- lung cancer (19%).
- G12D/G12V/G12C/G13D are the most common mutation types of K-RAS in pancreatic, lung and colorectal cancers.
- the series of compounds of the present invention have strong K-RAS enzymatic and cellular activity. Inhibitory effect, can be widely used in the preparation of drugs for the treatment of cancers or tumors mediated at least in part by the K-RAS G12C mutation, especially in the treatment of the lungs, hepatobiliary, gastrointestinal tract, blood system, skin, bone, genitourinary tract, nerve Drugs for systemic, gynecological and adrenal-related malignancies or cancers are expected to be developed into a new generation of K-RAS G12C inhibitor drugs.
- a first aspect of the present invention provides a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
- X is C(R 9 ) or N;
- R 1 is selected from hydrogen, deuterium, halogen, cyano, hydroxyl, C 1-4 alkyl, halogen substituted C 1-4 alkyl, deuterium substituted C 1-4 alkyl, C 1-4 alkoxy, halogen substituted C 1-4 alkoxy, deuterium substituted C 1-4 alkoxy, C 3-6 cycloalkyl, 4-6 membered heterocyclyl, acetamido and -SF 5 ;
- R 2a is selected from hydrogen, deuterium, halogen, cyano, hydroxyl, C 1-4 alkyl, halogen substituted C 1-4 alkyl, deuterium substituted C 1-4 alkyl, C 1-4 alkoxy, halogen substituted C 1-4 alkoxy, deuterium substituted C 1-4 alkoxy, C 3-6 cycloalkyl, 4-6 membered heterocyclyl, acetamido and -SF 5 ;
- R 2b is selected from hydrogen, deuterium, halogen, cyano, hydroxyl, C 1-4 alkyl, halogen substituted C 1-4 alkyl, deuterium substituted C 1-4 alkyl, C 1-4 alkoxy, halogen substituted C 1-4 alkoxy, deuterium substituted C 1-4 alkoxy, C 3-6 cycloalkyl, 4-6 membered heterocyclyl, acetamido and -SF 5 ;
- R 2c is selected from hydrogen, deuterium, halogen, cyano, hydroxy, C 1-4 alkyl, halogen substituted C 1-4 alkyl, deuterium substituted C 1-4 alkyl, C 1-4 alkoxy, halogen substituted C 1-4 alkoxy, deuterium substituted C 1-4 alkoxy, C 3-6 cycloalkyl, 4-6 membered heterocyclyl, acetamido and -SF 5 ;
- R 3 , R 4 , R 5 and R 6 are not simultaneously hydrogen
- n 0, 1, 2, 3 or 4;
- Each R 7 is independently selected from hydrogen, deuterium, halogen, cyano, hydroxy, C 1-4 alkoxy, C 1-4 alkyl, C 3-6 cycloalkyl, 4-6 membered heterocyclyl , -SF 5 , C 2-4 alkynyl, cyano substituted C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, halo substituted C 1-4 alkyl and deuterium substituted C 1-4 alkyl, Alternatively, when m ⁇ 2, the two R 7 together with the moiety to which they are attached form a C 3-12 cycloalkyl or 3-12 membered heterocyclyl;
- Each R 10 is independently selected from hydrogen, deuterium, hydroxyl, C 1-10 alkyl, C 2-10 alkenyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 5-10 Aryl, 5-10 membered heteroaryl and -NR 13 R 14 , the above-mentioned groups are optionally further selected from one or more groups selected from deuterium, halogen, hydroxyl, oxo, cyano, C 1-10 alkyl, C 1-10 alkoxy, C 3-12 cycloalkyl, C 3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C 5-10 aryl, C 5 -10 -aryloxy, 5-10-membered heteroaryl, 5-10-membered heteroaryloxy and -NR 13 R 14 substituents;
- Each R 11 is independently selected from hydrogen, deuterium, C 1-10 alkyl, C 2-10 alkenyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 5-10 aryl and 5-10-membered heteroaryl, the above-mentioned groups are optionally further selected from one or more groups selected from deuterium, halogen, hydroxyl, oxo, cyano, C 1-10 alkyl, C 1-10 alkoxy, C 3-12 cycloalkyl, C 3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C 5-10 aryl, C 5-10 aryloxy, 5- 10-membered heteroaryl, 5-10-membered heteroaryloxy and -NR 13 R 14 substituents;
- Each R 12 is independently selected from hydrogen, deuterium, hydroxyl, C 1-10 alkyl, C 1-10 alkoxy, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 Cycloalkyl, C 3-12 cycloalkoxy, 3-12-membered heterocyclyl, 3-12-membered heterocyclyloxy, C 5-10 aryl, C 5-10 aryloxy, 5-10-membered heterocycle Aryl, 5-10 membered heteroaryloxy and -NR 13 R 14 , the above-mentioned groups are optionally further selected by one or more groups selected from deuterium, halogen, hydroxyl, cyano, C 1-10 alkyl, C 1- 10 alkoxy, C 3-12 cycloalkyl, C 3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C 5-10 aryl, C 5-10 substituted by the substituents of aryloxy, 5-10-membered
- R 13 and R 14 is independently selected from hydrogen, deuterium, hydroxy, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 cycloalkyl, 3 -12-membered heterocyclyl, C 5-10 -membered aryl, 5-10-membered heteroaryl, sulfonyl, methanesulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, amino, C 1- 8 alkyl mono-substituted amino, C 1-8 alkyl disubstituted amino and C 1-10 alkanoyl, the above-mentioned groups are optionally further selected from one or more groups selected from deuterium, halogen, hydroxyl, C 1-8 alkyl, C 1-10 alkoxy, C 3-12 cycloalkyl, C 3-12 cycloalkoxy, 3-12-
- Each r is independently 0, 1, or 2.
- R 3 , R 4 , R 5 and R 6 are not simultaneously hydrogen
- R 10 , R 11 , R 12 , R 13 , R 14 and r are as defined for compounds of formula (I).
- R 1 is selected from hydrogen, deuterium, fluorine, chlorine, cyano, hydroxyl, C 1- 4 alkyl, halogen substituted C 1-4 alkyl, deuterium substituted C 1-4 alkyl, C 1-4 alkoxy, halogen substituted C 1-4 alkoxy, deuterium substituted C 1-4 alkoxy, C 3-6 cycloalkyl, 4-6 membered heterocyclyl and -SF 5 ;
- R 2a is selected from hydrogen, deuterium, fluorine, chlorine, cyano, hydroxyl, C 1-4 alkyl, halo-substituted C 1-4 alkyl, deuterium-substituted C 1-4 alkyl, C 1-4 alkoxy, Halogen-substituted C 1-4 alkoxy, deuterium-substituted C 1-4 alkoxy, C 3-6 cycloalkyl, 4-6 membered heterocyclyl and -SF 5 ;
- R 2b is selected from hydrogen, deuterium, fluorine, chlorine, cyano, hydroxy, C 1-4 alkyl, halogen substituted C 1-4 alkyl, deuterium substituted C 1-4 alkyl, C 1-4 alkoxy, Halogen-substituted C 1-4 alkoxy, deuterium-substituted C 1-4 alkoxy, C 3-6 cycloalkyl, 4-6 membered heterocyclyl and -SF 5 ;
- R 2c is selected from hydrogen, deuterium, fluorine, chlorine, cyano, hydroxy, C 1-4 alkyl, halogen substituted C 1-4 alkyl, deuterium substituted C 1-4 alkyl, C 1-4 alkoxy, Halo-substituted C 1-4 alkoxy, deuterium-substituted C 1-4 alkoxy, C 3-6 cycloalkyl, 4-6 membered heterocyclyl and -SF 5 .
- each R 7 is independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, C 1-4 alkoxy, C 1-4 alkyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 4-6 membered heterocyclyl, -SF 5 and cyano substituted C 1-4 Alkyl, or, when m ⁇ 2, two R 7 together with the moiety to which they are attached form a C 3-6 cycloalkyl or 3-6 membered heterocyclyl.
- each R 7 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano , hydroxy, methyl, ethyl, isopropoxy, cyclopropyl, cyclobutyl, cyclobutoxy, cyanomethyl and -SF5 .
- R 10 , R 11 , R 12 , R 13 , R 14 and r are as defined for compounds of formula (I).
- the compound of formula (I) has the following structure of compound of formula (II):
- X is CH or N
- R 1 is selected from hydrogen, deuterium, fluorine, chlorine, cyano, hydroxy, methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, methoxy , ethoxy, isopropoxy, trifluoromethoxy, difluoromethoxy, trideuteromethoxy, dideuteromethoxy, trifluoroisopropoxy, trideuterioisopropoxy, cyclopropyl radical, cyclobutyl and cyclobutoxy;
- R 2a is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, hydroxy, methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, methoxy , ethoxy, isopropoxy, trifluoromethoxy, difluoromethoxy, trideuteromethoxy, dideuteromethoxy, trifluoroisopropoxy, trideuterioisopropoxy, cyclopropyl radical, cyclobutyl and cyclobutoxy;
- R 2b is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, hydroxy, methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, methoxy , ethoxy, isopropoxy, trifluoromethoxy, difluoromethoxy, trideuteromethoxy, dideuteromethoxy, trifluoroisopropoxy, trideuterioisopropoxy, cyclopropyl radical, cyclobutyl and cyclobutoxy;
- R 3 , R 4 , R 5 and R 6 are not simultaneously hydrogen
- R 7a is selected from hydrogen, deuterium, fluorine, chlorine, cyano, hydroxy, methyl, ethyl, isopropoxy, cyclopropyl, cyclobutyl and cyclobutoxy;
- R 7b is selected from hydrogen, deuterium, fluorine, chlorine, cyano, hydroxy, methyl, ethyl, isopropoxy, cyclopropyl, cyclobutyl and cyclobutoxy;
- R 8 is selected from hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteromethyl, di-deuteromethyl, cyclopropyl, cyclobutyl, nitrogen Heterobutyl, oxetanyl, methoxy, ethoxy and isopropoxy;
- R 10 , R 11 , R 12 , R 13 , R 14 and r are as defined for compounds of formula (I).
- the compound of formula (I) has the following compound structure of formula (III):
- R 1 is hydrogen, deuterium, fluorine or chlorine
- R 2a is hydrogen, deuterium, fluorine or chlorine
- R 2b is selected from hydrogen, deuterium, fluorine, chlorine, cyano, hydroxyl, methyl, trifluoromethyl, methyl Oxy, trifluoromethoxy and cyclopropyl
- R 7a is selected from hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, isopropoxy, cyclopropyl, cyclobutyl and cyclobutoxy
- R 3 , R 4 , R 5 and R 6 are as defined for compounds of formula (II).
- R 5 is selected from -OR 11 and -OC(O)R 12 , the above-mentioned groups
- R 3 is selected from hydrogen, deuterium, -OR 11 and -OC(O)R 12
- R 10 , R 11 , R 12 , R 13 , R 14 and r are as defined for the compound of formula (II).
- R 5 is selected from hydroxyl, R is selected from hydrogen and deuterium ;
- R is selected from hydrogen, deuterium, hydroxyl
- R4 is selected from hydrogen and deuterium, alternatively, R3 and R4 are taken together with the carbon atom to which they are directly attached to form C(O), cyclopropyl, cyclobutyl, azetidine or oxetanyl.
- R 5 and R 6 together with their directly connected carbon atoms form C(O);
- R 3 is selected from hydrogen, deuterium, -OR 11 and -OC(O)R 12
- R 10 , R 11 , R 12 , R 13 , R 14 and r are as defined for the compound of formula (II).
- R 5 and R 6 together with their directly connected carbon atoms form C(O) ;
- R is selected from hydrogen, deuterium, hydroxyl
- R4 is selected from hydrogen and deuterium, alternatively, R3 and R4 are taken together with the carbon atom to which they are directly attached to form C(O), cyclopropyl, cyclobutyl, azetidine or oxetanyl.
- R 4 and R 5 together with their directly connected moieties form a 3-6 membered cycloalkane base or 3-6-membered heterocyclic group
- R 10 , R 11 , R 12 , R 13 , R 14 and r are as defined for the compound of formula (II).
- each R 10 is independently selected from hydrogen, deuterium, hydroxyl, C 1-4 alkane group, C 2-4 alkenyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 5-8 aryl, 5-8 membered heteroaryl and -NR 13 R 14 , the above-mentioned groups optionally further selected by one or more selected from deuterium, halogen, hydroxy, oxo, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 ring Alkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 5-8 aryl, C 5-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryl Oxygen and -NR 13 R 14 substituents are substituted;
- Each R 11 is independently selected from hydrogen, deuterium, C 1-4 alkyl, C 2-4 alkenyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 5-8 aryl and 5-8-membered heteroaryl, the above-mentioned groups are optionally further selected from one or more groups selected from deuterium, halogen, hydroxyl, oxo, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 5-8 aryl, C 5-8 aryloxy, 5- 8-membered heteroaryl, 5-8-membered heteroaryloxy and substituents of -NR 13 R 14 ;
- Each R 12 is independently selected from hydrogen, deuterium, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 Cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 5-8 aryl, C 5-8 aryloxy, 5-8 membered heterocycle Aryl, 5-8 membered heteroaryloxy and -NR 13 R 14 , the above-mentioned groups are optionally further selected by one or more groups selected from deuterium, halogen, hydroxyl, cyano, C 1-4 alkyl, C 1- 4 -alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6-membered heterocyclyl, 3-6-membered heterocyclyloxy, C 5-8 aryl, C 5-8 substituted by the substituents of aryloxy, 5-8-membere
- Each of R 13 and R 14 is independently selected from hydrogen, deuterium, hydroxyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3 -6-membered heterocyclyl, C 5-8 aryl, 5-8 membered heteroaryl, sulfonyl, methanesulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, amino, C 1- 4 alkyl mono-substituted amino, C 1-4 alkyl disubstituted amino and C 1-4 alkanoyl, the above-mentioned groups are optionally further selected from one or more groups selected from deuterium, halogen, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocycl
- the above-mentioned 4-6-membered heterocyclic group is optionally further selected from one or more groups selected from deuterium, halogen, hydroxyl, C 1- 4 alkyl, C 1-4 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C 5-8 Aryl, C 5-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 alkyl monosubstituted amino, C 1-4 alkyl disubstituted amino and Substituents of C 1-4 alkanoyl.
- the compounds of formula (I), their stereoisomers or their pharmaceutically acceptable salts include but are not limited to the following compounds:
- the second aspect of the present invention provides the preparation method of the compound of formula (I), its stereoisomer or its pharmaceutically acceptable salt, comprising the steps:
- R is H or amino protecting group, preferably, the amino protecting group is tert-butoxycarbonyl;
- R 1 , R 2a , R 2b , R 2c , R 3 , R 4 , R 5 , R 6 , R 7 , R8 , X and m are as described for compounds of formula (I).
- the third aspect of the present invention provides a pharmaceutical composition, which comprises the aforementioned compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- the fourth aspect of the present invention provides a compound of the aforementioned formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof or the aforementioned pharmaceutical composition in the preparation of a medicament for the treatment of tumors or cancers mediated at least in part by K-RAS G12C mutation use in.
- the cancer or tumor is selected from lung cancer or cancer, hepatobiliary cancer or cancer, gastrointestinal cancer or cancer, hematological cancer or cancer, sarcoma, skin cancer or cancer, bone cancer or cancer Malignant tumors or cancers, genitourinary malignancies or cancers, nervous system malignancies or cancers, gynecological malignancies or cancers, and adrenal malignancies or cancers.
- the lung malignant tumor or cancer is selected from bronchial carcinoma (squamous cell carcinoma, undifferentiated small cell, undifferentiated large cell or adenocarcinoma), non-small cell lung cancer, bronchial carcinoma, bronchial gland carcinoma tumor, sarcoma, lymphoma, cartilaginous hamartoma or mesothelioma;
- bronchial carcinoma squamous cell carcinoma, undifferentiated small cell, undifferentiated large cell or adenocarcinoma
- non-small cell lung cancer bronchial carcinoma, bronchial gland carcinoma tumor, sarcoma, lymphoma, cartilaginous hamartoma or mesothelioma
- bronchial carcinoma squamous cell carcinoma, undifferentiated small cell, undifferentiated large cell or adenocarcinoma
- non-small cell lung cancer bronchial carcinoma
- bronchial gland carcinoma tumor sarcoma
- the hepatobiliary malignancy or cancer is selected from liver cancer, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, gallbladder carcinoma, ampullary carcinoma or cholangiocarcinoma;
- the gastrointestinal malignancy or cancer is selected from the group consisting of esophageal malignancies or cancers (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma or lymphoma), gastric malignancies or cancers (carcinoma, lymphoma or leiomyosarcoma), pancreatic malignancies or cancer (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid, uveoma), small bowel (adenocarcinoma, lymphoma, carcinoid, Kaposi's sarcoma, leiomyoma , hemangioma, lipoma, neurofibroma, fibroma), colorectal cancer malignancy or cancer (adenocarcinoma, adenoma, adenoma, tubular adenoma) or leiomyoma;
- Said hematological malignancy or cancer is selected from acute or chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative disease, multiple myeloma, myelodysplastic syndrome, Hodgkin's disease or non-Hodgkin's disease Chikin lymphoma;
- Said sarcoma is selected from the group consisting of angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma, myxoma, rhabdomyosarcoma, fibroma, lipoma or teratoma;
- the skin malignancy or cancer is selected from malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, nevus, nevus hyperplasia, lipoma, hemangioma, dermatofibroma, keloid, or psoriasis;
- the bone malignancy or cancer is selected from the group consisting of osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, multiple myeloma, malignant giant cell tumor chordoma, osteochondroma, Benign chondroma, chondroblastoma, chondromucosal fibroma, osteoid osteoma, or giant cell tumor;
- the urogenital malignancy or cancer is selected from the group consisting of renal malignancies or cancers (adenocarcinoma, Wilms tumor or Wilms tumor), lymphoma, leukemia, bladder or urinary tract malignancies or cancers (squamous cell carcinoma, transitional cell carcinoma or adenocarcinoma), prostate malignancy or cancer (adenocarcinoma or sarcoma), testicular malignancy or cancer (blood cancer, teratoma, embryonal carcinoma or teratoma), choriocarcinoma, sarcoma, stromal cell carcinoma, Fibroma, fibroadenoma, adenomatous tumor or lipoma;
- the nervous system malignancy or cancer is selected from the group consisting of osteoma, hemangioma, granuloma, xanthoma, osteitis deformans, meningioma, meningiosarcoma, gliomatosis, astrocytoma, medulloblastoma, glia Plasma tumor, ependymoma, genital tumor, glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumor, spinal neurofibroma, meningioma, glial tumor or sarcoma;
- the gynecological malignancy or cancer is selected from endometrial carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma or unclassified carcinoma), granular-schwannoma, Leydig cell tumor, sarcolemma, malignant tumor Teratoma, squamous cell carcinoma, fibroepithelial carcinoma, adenocarcinoma, melanoma, clear cell carcinoma, squamous cell carcinoma, grape sarcoma, or fallopian tube carcinoma;
- the adrenal malignancy or cancer is selected from neuroblastoma.
- a fifth aspect of the present invention provides a compound of the aforementioned formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for use in the treatment of tumors or cancers mediated at least in part by K-RAS G12C mutation medicine.
- a sixth aspect of the present invention provides a method of preventing and/or treating a tumor or cancer mediated at least in part by K-RAS G12C mutation, comprising administering to a patient a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable compound thereof Accept the salt, or the aforementioned pharmaceutical composition.
- the series of compounds of the present invention have a strong inhibitory effect on K-RAS enzymatic and cellular activities, and can be widely used in the preparation of medicines for the treatment of cancers or tumors at least partially mediated by K-RAS G12C mutation, especially for the treatment of lung, Drugs for hepatobiliary, gastrointestinal, blood system, skin, bone, genitourinary tract, nervous system, gynecological and adrenal-related malignancies or cancers are expected to be developed into a new generation of K-RAS G12C inhibitor drugs. On this basis, the present invention has been completed.
- Alkyl refers to a straight-chain or branched-chain saturated aliphatic hydrocarbon group, preferably a straight-chain alkyl group and a branched-chain alkyl group comprising 1 to 10 or 1 to 6 carbon atoms or 1 to 4 carbon atoms, Including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1, 2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methyl propylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3- Dimethylbutyl,
- C 1-10 alkyl refers to straight-chain alkyl groups including 1 to 10 carbon atoms and branched alkyl groups
- C 1-8 alkyl refers to straight-chain alkyl groups including 1 to 8 carbon atoms and A branched-chain alkyl group
- C 0-8 alkyl refers to a straight-chain alkyl group of 0 to 8 carbon atoms and a branched alkyl group
- C 0-4 alkyl refers to 0 to 4 carbon atoms
- C 0-2 alkyl group refers to the straight-chain alkyl group with 0 to 2 carbon atoms and the branched-chain alkyl group
- C 1-4 alkyl group refers to including Straight-chain and branched-chain alkyl groups of 1 to 4 carbon atoms
- C 0 alkyl means 0 carbon atoms.
- Cycloalkyl or “carbocycle” refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, and the partially unsaturated cyclic hydrocarbon means that the cyclic hydrocarbon may contain one or more (preferably 1, 2 or 3) double bonds, but none of the rings has a completely conjugated ⁇ electron system, and the cycloalkyl group is divided into monocyclic cycloalkyl, polycyclic cycloalkyl, preferably including 3 to 10 or 3 to 8 or 3 Cycloalkyl groups of up to 6 carbon atoms, for example, “C 3-10 cycloalkyl” refers to cycloalkyl groups including 3 to 10 carbon atoms, “C 3-8 cycloalkyl” refers to cycloalkyl groups including 3 to 8 carbon atoms Atom cycloalkyl, "C 3-6 cycloalkyl” refers to a cycloalkyl group comprising 3 to 6 carbon atoms, wherein
- Monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, Cyclooctyl etc.
- Polycyclic cycloalkyl groups include spiro, fused and bridged cycloalkyl groups.
- “Spirocycloalkyl” refers to polycyclic groups in which a single carbon atom (called a spiro atom) is shared between the monocyclic rings, these may contain one or more (preferably 1, 2 or 3) double bonds, but none of the rings have Fully conjugated pi electron system. According to the number of spiro atoms shared between the rings, spirocycloalkyl groups are classified into single spirocycloalkyl groups, double spirocycloalkyl groups or polyspirocycloalkyl groups, and spirocycloalkyl groups include but are not limited to:
- fused cycloalkyl refers to an all-carbon polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more rings may contain one or more (preferably 1, 2 or 3) double bonds, but none of the rings have a fully conjugated pi electron system. According to the number of formed rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl groups, fused cycloalkyl groups include but are not limited to:
- “Bridged cycloalkyl” refers to an all-carbon polycyclic group in which any two rings share two non-directly attached carbon atoms, these may contain one or more (preferably 1, 2 or 3) double bonds, but none The ring has a fully conjugated pi electron system. According to the number of formed rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, including but not limited to:
- the cycloalkyl ring can be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl, including but not limited to indanyl, tetrahydronaphthyl , benzocycloheptyl, etc.
- a heterocyclyl group includes 3 to 10 or 3 to 8 or 3 to 6 ring atoms, for example, "3-6 membered heterocyclyl” refers to a ring group containing 3 to 6 ring atoms, "4-6 membered hetero
- Monocyclic heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like.
- Polycyclic heterocyclyls include spiro, fused and bridged heterocyclyls.
- Spiroheterocyclyls are classified into mono-, bis-, or poly-spiroheterocyclyls according to the number of spiro atoms shared between the rings.
- Spiroheterocyclyl groups include, but are not limited to:
- the heterocyclyl ring can be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclyl, including but not limited to:
- Aryl or “aromatic ring” refers to an all-carbon monocyclic or fused polycyclic (ie, rings sharing adjacent pairs of carbon atoms) groups, polycyclic rings having a conjugated pi electron system (ie, with adjacent ring) groups for carbon atoms, preferably all-carbon aryl groups containing 5-10 or 5-8 carbons, for example, "C 5-10 aryl” refers to all-carbon aryl groups containing 5-10 carbons, Including but not limited to phenyl and naphthyl.
- the aryl ring can be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, including but not limited to:
- Heteroaryl refers to a heteroaromatic system containing one or more (preferably 1, 2, 3 or 4) heteroatoms including nitrogen, oxygen and S(O)r (where r is the integer 0 , 1, 2) heteroatoms, preferably a heteroaromatic system containing 5-10 or 5-8 ring atoms, for example, a 5-10 membered heteroaryl group refers to a heteroaromatic system containing 5-10 ring atoms , including but not limited to furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl and the like.
- the heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, including but not limited to:
- Alkenyl means an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, preferably a straight or branched chain alkenyl group containing 2-10 or 2-4 carbons
- C 2-10 alkenyl refers to a straight-chain or branched alkenyl containing 2-10 carbons
- C 2-4 alkenyl refers to a straight or branched alkenyl containing 2-4 carbons .
- Alkynyl means an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, preferably a straight-chain or branched-chain alkynyl group containing 2-10 or 2-4 carbons,
- a C2-10 alkynyl group refers to a straight or branched chain alkynyl group containing 2 to 10 carbons
- a C2-4 alkynyl group refers to a straight chain or branched chain alkynyl group containing 2 to 4 carbons.
- ethynyl 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, and the like.
- Alkoxy refers to -O-alkyl, where alkyl is as defined above, eg, "C 1-10 alkoxy” refers to an alkyloxy group containing 1-10 carbons, C 1-4 alkoxy "Oxy” refers to an alkyloxy group containing 1-4 carbons including, but not limited to, methoxy, ethoxy, propoxy, butoxy, and the like.
- Cycloalkoxy refers to -O-cycloalkyl, where cycloalkyl is as defined above, for example, "C 3-10 cycloalkoxy” refers to a cycloalkyloxy group containing 3-10 carbons, Including, but not limited to, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and the like.
- Heterocyclyloxy refers to -O-heterocyclyl, wherein heterocyclyl is as defined above, and heterocyclyloxy, including but not limited to azetidinyloxy, oxetanyloxy, nitrogen Heterocyclopentyloxy, nitrogen, oxhexyloxy, etc.
- C 1-10 alkanoyl refers to the monovalent atomic group remaining after C 1-10 alkyl acid removes the hydroxyl group, usually also expressed as “C 0-9 alkyl-C(O)-", for example, “C 1 "Alkyl-C(O)-” means acetyl; “ C2alkyl -C(O)-” means propionyl; “ C3alkyl -C(O)-” means butyryl or isobutyl Acyl.
- Halo-substituted C 1-4 alkyl refers to 1-4 carbon alkyl groups in which the hydrogen on the alkyl group is optionally substituted by fluorine, chlorine, bromine, or iodine atoms, including but not limited to difluoromethyl (-CHF 2 ), dichloromethyl (-CHCl 2 ), dibromomethyl (-CHBr 2 ), trifluoromethyl (-CF 3 ), trichloromethyl (-CCl 3 ), tribromomethyl (-CBr 3 ) etc.
- Halo-substituted C 1-4 alkoxy refers to a 1-4 carbon alkoxy group in which the hydrogen on the alkyl group is optionally substituted by fluorine, chlorine, bromine, or iodine atoms. Including but not limited to difluoromethoxy, dichloromethoxy, dibromomethoxy, trifluoromethoxy, trichloromethoxy, tribromomethoxy and the like.
- Deuterium substituted C1-4 alkyl refers to a 1-4 carbon alkyl group in which the hydrogen on the alkyl group is optionally replaced by a deuterium atom. Including, but not limited to, deuteromethyl ( -CH2D ), dideuteromethyl ( -CHD2 ), trideuteromethyl ( -CD3 ), and the like.
- Deuterium substituted C 1-4 alkoxy refers to a 1-4 carbon alkyl group in which the hydrogen on the alkyl group is optionally substituted with a deuterium atom. Including but not limited to mono-deuteromethoxy, di-deuteromethoxy, tri-deuteromethoxy and the like.
- Halogen refers to fluorine, chlorine, bromine or iodine.
- MeOH refers to methanol.
- KF refers to potassium fluoride.
- KHMDS refers to potassium hexamethyldisilazide.
- NBS refers to N-bromosuccinimide.
- DMF refers to N,N-dimethylformamide.
- Grubbs 2nd Generation Catalyst means Grubbs 2nd Generation Catalyst.
- IBX refers to 2-iodoylbenzoic acid.
- Optional or “optionally” means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur, that is, both substituted and unsubstituted .
- a heterocyclic group optionally substituted with an alkyl group means that an alkyl group may, but need not, be present, and the description includes the case where the heterocyclic group is substituted with an alkyl group and the case where the heterocyclic group is not substituted with an alkyl group .
- Substituted means that one or more "hydrogen atoms" in a group are, independently of one another, substituted with the corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, in accordance with valence bond theory in chemistry, and those skilled in the art can determine (either experimentally or theoretically) possible or impossible without undue effort replacement. For example, amino or hydroxyl groups with free hydrogen may be unstable when combined with carbon atoms with unsaturated bonds, such as alkenes.
- Stereoisomer its English name is stereoisomer, refers to the isomers produced by the different arrangements of atoms in the molecule in space. It can be divided into cis-trans isomers and enantiomers. It can also be divided into two categories: enantiomers and diastereomers. Stereoisomers due to rotation of a single bond are called conformational stereo-isomers, and are sometimes called rotamers. Stereoisomers caused by bond length, bond angle, double bond in the molecule, ring, etc. are called configuration stereo-isomers, and configuration isomers are divided into two categories.
- the isomers caused by the double bond or the single bond of the ring carbon atom not being able to rotate freely are called geometric isomers, also known as cis-trans isomers, which are divided into Z, E two configurations.
- geometric isomers also known as cis-trans isomers, which are divided into Z, E two configurations.
- cis-2-butene and trans-2-butene are a pair of geometric isomers, if the compound of the present invention contains a double bond, if not specified, it can be understood as containing E and/or Z form.
- Stereoisomers with different optical properties due to the absence of anti-axial symmetry in the molecule are called optical isomers and are divided into R and S configurations.
- the "stereoisomer" can be understood to include one or more of the above-mentioned enantiomers, configuration isomers and conformation isomers unless otherwise specified, preferably R configuration type.
- “Pharmaceutically acceptable salts” in the present invention refer to pharmaceutically acceptable acid addition salts or base addition salts, including inorganic and organic acid salts, which can be prepared by methods known in the art.
- “Pharmaceutical composition” means a mixture containing one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, with other chemical components, and other components such as a physiological/pharmaceutically acceptable carrier and excipients.
- the purpose of the pharmaceutical composition is to facilitate the administration to the organism, facilitate the absorption of the active ingredient and then exert the biological activity.
- the structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) or/and liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts ([delta]) are given in parts per million (ppm). NMR was measured by Bruker AVANCE-400/500 nuclear magnetic instrument, the solvent was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated methanol (CD 3 OD) and deuterated chloroform (CDCl 3 ), internal standard For tetramethylsilane (TMS).
- DMSO-d 6 dimethyl sulfoxide
- CD 3 OD deuterated methanol
- CDCl 3 deuterated chloroform
- TMS internal standard For tetramethylsilane
- the thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, the specifications used for TLC are 0.15mm ⁇ 0.20mm, and the specifications used for TLC separation and purification products are 0.4mm ⁇ 0.5mm.
- Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
- the starting materials in the examples of the present invention are known and commercially available, or can be synthesized using or according to methods known in the art.
- the first step the synthesis of 2-bromo-4-chloropyridin-3-amine
- the second step the synthesis of 4-chloro-2-(prop-1-en-2-yl)pyridin-3-amine
- the third step the synthesis of 4-chloro-2-isopropylpyridin-3-amine
- the fourth step the synthesis of 2-isopropyl-4-vinylpyridine-3-amine
- 2,6-Dichloro-5-fluoronicotinic acid (10.0 g, 47.6 mmol) was dissolved in dichloromethane (30 mL), a catalytic amount of DMF was added, and oxalyl chloride (6.3 g, 50 mmol) was slowly added under stirring at room temperature, After the addition was completed, the mixture was stirred at room temperature for 2 h.
- the second step Synthesis of 2,6-dichloro-5-fluoro-N-((2-isopropyl-4-vinylpyridin-3-yl)carbamoyl)nicotinamide
- 2,6-Dichloro-5-fluoronicotinamide (2.9 g, 14 mmol) was dissolved in tetrahydrofuran (30 mL), oxalyl chloride (1.9 g, 14.8 mmol) was added, heated to reflux for 2 h, the reaction mixture was cooled to 0 °C, 2-Isopropyl-4-vinylpyridin-3-amine (2.9 g, 14 mmol) was added, and the mixture was naturally warmed to room temperature and stirred for 1 h.
- the seventh step tert-butyl(S,Z)-4-( 26,36 -difluoro- 12 -isopropyl- 22 - oxo - 21,22 - dihydro-4- Oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2)-benzocycloheptane-6-ene-2 4 - Synthesis of yl)-3-methylpiperazine-1-carboxylate
- Intermediate B2 can be prepared with reference to all or part of the synthesis methods of intermediate B1 and select corresponding raw materials:
- the first step tert-butyl(3S)-4-( 26,36 -difluoro- 6,7 -dihydroxy- 12 -isopropyl- 22 - oxo- 21,22- Dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2)-benzocycloheptane-2 4 -Synthesis of -3-methylpiperazine-1-carboxylate
- Intermediates C2-C10 can be prepared with reference to all or part of the synthesis methods of intermediate C1 by selecting corresponding raw materials:
- Intermediates D2-D10 can be prepared by selecting corresponding raw materials with reference to all or part of the synthesis methods of intermediate D1:
- Example 1 24 -((S)-4-Acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro- 6,7 -dihydroxy- 12 -isopropyl Base-2 1 ,2 2 -dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2)- Preparation of benzocycloheptane-2 2 -one
- the first step 24 -((S)-4-acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro- 6,7 -dihydroxy- 12 -isopropyl Base-2 1 ,2 2 -dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2)- Synthesis of Benzocycloheptane-2 2 -one
- Embodiment 1-R and 1-S are separated and obtained by SFC on the basis of embodiment 1 preparation:
- Embodiment 2-3 can select corresponding raw material to prepare with reference to all or part of the synthetic method of embodiment 1:
- Example 4 24-((S)-4-Acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro- 6 -hydroxy- 12 -isopropyl-2 1 ,2 2 -Dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2)-benzocycle Preparation of heptane-2 2 ,7-dione
- the first step tert-butyl(3S)-4-( 26,36 -difluoro- 6 -hydroxy- 12 -isopropyl- 22,7 - dioxo- 21,22- Dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2)-benzocycloheptane-2 4 -Synthesis of -3-methylpiperazine-1-carboxylate
- the second step 24 -((S)-4-acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro- 6 -hydroxy- 12 -isopropyl-2 1 ,2 2 -Dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2)-benzocycle Synthesis of Heptane-2 2 ,7-Dione
- Example 5 24 -((S)-4-Acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro- 7 -hydroxy- 12 -isopropyl-2 1 ,2 2 -Dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2)-benzocycle Preparation of heptane- 22 -one
- the first step tert-butyl(3S)-4-(26,36-difluoro- 7 -hydroxy- 12 -isopropyl- 22 - oxo - 21,22 - dihydro- 4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2)-benzocycloheptane- 24 -yl) Synthesis of -3-methylpiperazine-1-carboxylate
- the third step 24 -((S)-4-acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro- 7 -hydroxy- 12 -isopropyl-2 1 ,2 2 -Dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2)-benzocycle Synthesis of Heptane-2 2 -one
- Example 6 24 -((S)-4-Acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro- 6 -hydroxy- 12 -isopropyl-2 2 -oxo-2 1 ,2 2 -dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1, 2)
- the second step 24 -((S)-4-acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro- 6 -hydroxy- 12 -isopropyl-2 2 -oxo-2 1 ,2 2 -dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1, 2) Synthesis of -benzocycloheptane-7-yl propionate
- Embodiment 7-17 can select corresponding raw material to prepare with reference to all or part of the synthetic method of embodiment 6:
- Example 18 24 -((S)-4-Acryloyl- 2-methylpiperazin-1-yl)-26,36-difluoro-12 - isopropyl - 22 -oxo -2 1 ,2 2 -Dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2)-benzene Preparation of cycloheptane-6,7-diyldiacetate
- Embodiment 18-R and 18-S are separated and obtained by SFC on the basis of the preparation of embodiment 18:
- Example 19 24 -((S)-4-Acryloyl- 2-methylpiperazin-1-yl)-26,36-difluoro-12 - isopropyl - 22,6- Dioxo-2 1 ,2 2 -dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2 Preparation of )-benzocycloheptan-7-yl acetate
- Example 20 is separated and obtained by SFC on the basis of the preparation of Example 19:
- Embodiments 21-22 can be prepared by selecting corresponding raw materials with reference to all or part of the synthetic methods of Embodiments 19-20:
- Example 23 24 -((S)-4-Acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro- 6 -hydroxy- 12 -isopropyl-2 2 -oxo-2 1 ,2 2 -dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1, 2)
- the first step tert-butyl(3S)-4-(7-(((((9H-fluoren-9-yl)methoxy)carbonyl)-L-valyl)oxo)-2 6 , 3 6 -Difluoro-6-hydroxy-1 2 -isopropyl-2 2 -oxo-2 1 ,2 2 -dihydro-4-oxa-2(1,7)-pyrido[2,3 Synthesis of -d]pyrimidine-1(3,4)-pyridine-3(1,2)-benzocycloheptane- 24 -yl)-3-methylpiperazine-1-carboxylate
- the third step 24 -((S)-4-acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro- 6 -hydroxy- 12 -isopropyl-2 2 -oxo-2 1 ,2 2 -dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1, 2) Synthesis of-benzocycloheptan-7-yl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-valine ester
- the fourth step 24 -((S)-4-acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro- 6 -hydroxy- 12 -isopropyl-2 2 -oxo-2 1 ,2 2 -dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1, 2) Synthesis of -benzocycloheptane-7-yl L-valine ester
- Example 24 24 -((S)-4-Acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro-7-(2-fluoroethoxy) -6 -Hydroxy-1 2 -isopropyl-2 1 ,2 2 -dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine Preparation of -3(1,2)-benzocycloheptan- 22 -one
- Embodiments 25-36 can be prepared by selecting corresponding raw materials with reference to all or part of the synthetic methods of Example 24:
- Embodiments 37-58 are separated and obtained by SFC on the basis of the preparation of embodiments 24-36:
- Example 59 24 -((S)-4-Acryloyl-2-methylpiperazin-1-yl) -26,36 -difluoro- 12 -isopropyl- 6,7 -di Methoxy-2 1 ,2 2 -dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1,2 Preparation of )-benzocycloheptane- 22 -one
- Embodiments 60-61 can be prepared by selecting corresponding raw materials with reference to all or part of the synthetic methods of Example 59:
- Example 62 11-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-15,21-difluoro-7-isopropyl-3a,20a-dihydro-9H, 20H-12,14-(Cycloethane[1,2]diylidene)benzo[b][1,3]dioxazolo[4,5-j]pyrido[3,4-h]pyrimidine Preparation of [6,1-f][1]oxa[5,7]diazacyclodidecyne-2,9-dione
- Example 63 11-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-15,21-difluoro-7-isopropyl-2,2-dimethyl-3a ,20a-dihydro-9H,20H-12,14-(cycloethane[1,2]diylidene)benzo[b][1,3]dioxazolo[4,5-j]pyrido Preparation of [3,4-h]pyrimido[6,1-f][1]oxa[5,7]diazacyclododecan-9-one
- Example 64 11-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-2-((dimethylamino)methyl)-15,21-difluoro-7-iso Propyl-3a,20a-dihydro-9H,20H-12,14-(cycloethane[1,2]diylidene)benzo[b][1,3]dioxazolo[4,5- Preparation of j]pyrido[3,4-h]pyrimido[6,1-f][1]oxa[5,7]diazacyclododecan-9-one
- the first step tert-butyl(3S)-4-(15,21-difluoro-7-isopropyl-9-oxo-2-vinyl-3a,20a-dihydro-9H,20H-12 ,14-(Cycloethane[1,2]diylidene)benzo[b][1,3]dioxazolo[4,5-j]pyrido[3,4-h]pyrimido[6 Synthesis of ,1-f][1]oxa[7]azcyclododecan-11-yl)-3-methylpiperazine-1-carboxylate
- the second step tert-butyl (3S)-4-(2-(1,2-dihydroxyethyl)-15,21-difluoro-7-isopropyl-9-oxo-3a,20a- Dihydro-9H,20H-12,14-(cycloethane[1,2]diylidene)benzo[b][1,3]dioxazolo[4,5-j]pyrido[3, Synthesis of 4-h]pyrimido[6,1-f][1]oxa[5,7]diazacyclododecan-11-yl)-3-methylpiperazine-1-carboxylate
- the third step tert-butyl (3S)-4-(15,21-difluoro-2-formyl-7-isopropyl-9-oxo-3a, 20a-dihydro-9H, 20H-12 ,14-(Cycloethane[1,2]diylidene)benzo[b][1,3]dioxazolo[4,5-j]pyrido[3,4-h]pyrimido[6 Synthesis of ,1-f][1]oxa[5,7]diazacyclododecan-11-yl)-3-methylpiperazine-1-carboxylate
- the fourth step tert-butyl (3S)-4-(2-((dimethylamino)methyl)-15,21-difluoro-7-isopropyl-9-oxo-3a,20a-di Hydrogen-9H,20H-12,14-(cycloethane[1,2]diylidene)benzo[b][1,3]dioxazolo[4,5-j]pyrido[3,4 Synthesis of -h]pyrimido[6,1-f][1]oxa[5,7]diazacyclododecan-11-yl)-3-methylpiperazine-1-carboxylate
- the fifth step 2-((dimethylamino)methyl)-15,21-difluoro-7-isopropyl-11-((S)-2-methylpiperazin-1-yl)-3a, 20a-Dihydro-9H,20H-12,14-(cycloethane[1,2]diylidene)benzo[b][1,3]dioxazolo[4,5-j]pyrido[ Synthesis of 3,4-h]pyrimido[6,1-f][1]oxa[5,7]diazacyclododecan-9-one
- the sixth step 11-((S)-4-acryloyl-2-methylpiperazin-1-yl)-2-((dimethylamino)methyl)-15,21-difluoro-7-iso Propyl-3a,20a-dihydro-9H,20H-12,14-(cycloethane[1,2]diylidene)benzo[b][1,3]dioxazolo[4,5- Synthesis of j]pyrido[3,4-h]pyrimido[6,1-f][1]oxa[5,7]diazacyclododecan-9-one
- Example 65 (R)-24-((2S,5R)-4 - acryloyl- 2,5 -dimethylpiperazin-1-yl)-35-chloro - 26,36 - di Fluoro-6,7-dihydroxy- 12 -isopropyl-21,22-dihydro-4-oxa- 2 ( 1,7 )-pyrido[2,3-d]pyrimidine-1( Preparation of 3,4)-pyridine-3(1,2)-benzocycloheptan-2 2 -one
- the first step (R)-tert-butyl(2R,5S)-4-( 35 -chloro-26,36-difluoro- 6,7 -dihydroxy- 12 -isopropyl- 2 2 -oxo-2 1 ,2 2 -dihydro-4-oxa-2(1,7)-pyrido[2,3-d]pyrimidine-1(3,4)-pyridine-3(1, Synthesis of 2)-benzocycloheptane- 24 -yl)-2,5-dimethylpiperazine-1-carboxylate
- the third step (R)-24-((2S,5R)-4 - acryloyl- 2,5 -dimethylpiperazin-1-yl)-35-chloro - 26,36 - di Fluoro-6,7-dihydroxy- 12 -isopropyl-21,22-dihydro-4-oxa- 2 ( 1,7 )-pyrido[2,3-d]pyrimidine-1( Synthesis of 3,4)-pyridine-3(1,2)-benzocycloheptan-2 2 -one
- Embodiments 66-71 can be prepared by selecting corresponding raw materials with reference to all or part of the synthetic methods of embodiment 65:
- Embodiments 72-79 are separated and obtained by SFC on the basis of the preparations of Embodiments 68-71:
- cells When cell confluence was about 80%, cells were detached with 0.25% trypsin. The isolated cells were resuspended in 5 mL of fresh cell culture medium and centrifuged to collect the cells. Simultaneously count the number of cells. The cells were then suspended in medium concentration medium. Cells were placed in 96-well plates at 1500 cells/well for H358 and 500 cells/well for MIAPACA-2. The 96-well plate was placed in an incubator at 37°C and incubated overnight.
- a 10-point serial dilution was made at a ratio of 1:3 from a 2 mM stock.
- 5X compound-containing medium was transferred to corresponding wells of 96 wells.
- the final peak compound concentration was 10 ⁇ M and the final concentration of DMSO was 0.5%.
- the 96-well plate was placed in a 37°C incubator for 5 days.
- Percent inhibition (%) at each compound concentration was calculated from the signal in HPE and ZPE control wells and the fluorescence signal in individual compound wells contained in each assay plate. ZPE control wells containing enzyme and substrate showed 0% inhibition, and HPE control wells containing only substrate showed 100% inhibition.
- the concentration of compound required for 50% inhibition ( IC50 ) was determined using a four-parameter log-dose-response equation from the concentration of the test compound and the percent inhibition value. Endpoint values ( IC50 ) for reference compounds were evaluated in each experiment as a quality control measure. The experiment was considered acceptable if the endpoint value was within three times the expected value.
- the series of compounds of the present invention have a strong inhibitory effect on the activity of K-RAS cells. several times the increase.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (21)
- 式(I)化合物、其立体异构体或其药学上可接受盐:其中,X为C(R 9)或N;R 1选自氢、氘、卤素、氰基、羟基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 1-4烷氧基、卤取代C 1-4烷氧基、氘取代C 1-4烷氧基、C 3-6环烷基、4-6元杂环基、乙酰胺基和-SF 5;R 2a选自氢、氘、卤素、氰基、羟基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 1-4烷氧基、卤取代C 1-4烷氧基、氘取代C 1-4烷氧基、C 3-6环烷基、4-6元杂环基、乙酰胺基和-SF 5;R 2b选自氢、氘、卤素、氰基、羟基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 1-4烷氧基、卤取代C 1-4烷氧基、氘取代C 1-4烷氧基、C 3-6环烷基、4-6元杂环基、乙酰胺基和-SF 5;R 2c选自氢、氘、卤素、氰基、羟基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 1-4烷氧基、卤取代C 1-4烷氧基、氘取代C 1-4烷氧基、C 3-6环烷基、4-6元杂环基、乙酰胺基和-SF 5;R 3和R 4各自独立地选自氢、氘、卤素、氰基、硝基、叠氮基、C 1-10烷基、C 2-10链烯基、C 2-10链炔基、C 3-12环烷基、3-12元杂环基、C 5-10芳基、5-10元杂芳基、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12,或者,R 3和R 4与其直接相连的碳原子一起形成C(O)、3-12元环烷基或3-12元杂环基,上述基团任选进一步被一个或多个选自氘、卤素、氰基、硝基、叠氮基、C 1-10烷基、卤取代C 1-10烷基、氘取代C 1-10烷基、C 2-10链烯基、C 2-10链炔基、C 3-12环烷基、3-12元杂环基、C 5-10芳基、5-10元杂芳基、=O、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12的取代基所取代;R 5和R 6各自独立地选自氢、氘、卤素、氰基、硝基、叠氮基、C 1-10烷基、C 2-10链烯基、C 2-10链炔基、C 3-12环烷基、3-12元杂环基、C 5-10芳基、5-10元杂芳基、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12,或者,R 5和R 6与其直接相连的碳原子一起形成C(O)、3-12元环烷基或3-12元杂环基,上述基团任选进一步被一个或多个选自氘、卤素、氰基、硝基、叠氮基、C 1-10烷基、卤取代C 1-10烷基、氘取代C 1-10烷基、C 2-10链烯基、C 2-10链炔基、C 3-12环烷基、3-12 元杂环基、C 5-10芳基、5-10元杂芳基、=O、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12的取代基所取代;条件是R 3、R 4、R 5和R 6不同时为氢;或者,R 4和R 5与其直接相连的部分一起形成3-12元环烷基或3-12元杂环基,上述3-12元环烷基或3-12元杂环基任选进一步被一个或多个选自氘、卤素、氰基、硝基、叠氮基、C 1-10烷基、卤取代C 1-10烷基、氘取代C 1-10烷基、C 2-10链烯基、C 2-10链炔基、C 3-12环烷基、3-12元杂环基、C 5-10芳基、5-10元杂芳基、=O、-C 0-8烷基-SF 5、-C 0-8烷基-S(O) rR 10、-C 0-8烷基-O-R 11、-C 0-8烷基-C(O)OR 11、-C 0-8烷基-C(O)R 12、-C 0-8烷基-O-C(O)R 12、-C 0-8烷基-NR 13R 14、-C 0-8烷基-C(=NR 13)R 12、-C 0-8烷基-N(R 13)-C(=NR 14)R 12、-C 0-8烷基-C(O)NR 13R 14和-C 0-8烷基-N(R 13)-C(O)R 12的取代基所取代,R 3和R 6如前所定义;m为0、1、2、3或4;每个R 7各自独立地选自氢、氘、卤素、氰基、羟基、C 1-4烷氧基、C 1-4烷基、C 3-6环烷基、4-6元杂环基、-SF 5、C 2-4链炔基、氰基取代C 1-4烷基、羟基取代C 1-4烷基、卤取代C 1-4烷基和氘取代C 1-4烷基,或者,当m≥2时,两个R 7与其相连的部分一起形成C 3-12环烷基或3-12元杂环基;R 8和R 9各自独立地选自氢、氘、卤素、氰基、硝基、叠氮基、C 1-10烷基、C 2-10链烯基、C 2-10链炔基、C 3-12环烷基、3-12元杂环基、C 5-10芳基、5-10元杂芳基、-C 0-8烷基-SF 5、-C 0-8烷基-S(O) rR 10、-C 0-8烷基-O-R 11、-C 0-8烷基-C(O)OR 11、-C 0-8烷基-C(O)R 12、-C 0-8烷基-O-C(O)R 12、-C 0-8烷基-NR 13R 14、-C 0-8烷基-C(=NR 13)R 12、-C 0-8烷基-N(R 13)-C(=NR 14)R 12、-C 0-8烷基-C(O)NR 13R 14和-C 0-8烷基-N(R 13)-C(O)R 12,上述基团任选进一步被一个或多个选自氘、卤素、氰基、硝基、叠氮基、C 1-10烷基、卤取代C 1-10烷基、氘取代C 1-10烷基、C 2-10链烯基、C 2-10链炔基、C 3-12环烷基、3-12元杂环基、C 5-10芳基、5-10元杂芳基、=O、-C 0-8烷基-SF 5、-C 0-8烷基-S(O) rR 10、-C 0-8烷基-O-R 11、-C 0-8烷基-C(O)OR 11、-C 0-8烷基-C(O)R 12、-C 0-8烷基-O-C(O)R 12、-C 0-8烷基-NR 13R 14、-C 0-8烷基-C(=NR 13)R 12、-C 0-8烷基-N(R 13)-C(=NR 14)R 12、-C 0-8烷基-C(O)NR 13R 14和-C 0-8烷基-N(R 13)-C(O)R 12的取代基所取代;每个R 10各自独立地选自氢、氘、羟基、C 1-10烷基、C 2-10链烯基、C 3-12环烷基、3-12元杂环基、C 5-10芳基、5-10元杂芳基和-NR 13R 14,上述基团任选进一步被一个或多个选自氘、卤素、羟基、氧代、氰基、C 1-10烷基、C 1-10烷氧基、C 3-12环烷基、C 3-12环烷氧基、3-12元杂环基、3-12元杂环氧基、C 5-10芳基、C 5-10芳氧基、5-10元杂芳基、5-10元杂芳氧基和-NR 13R 14的取代基所取代;每个R 11各自独立地选自氢、氘、C 1-10烷基、C 2-10链烯基、C 3-12环烷基、3-12元杂环基、C 5-10芳基和5-10元杂芳基,上述基团任选进一步被一个或多个选自氘、卤素、羟基、氧代、氰基、C 1-10烷基、C 1-10烷氧基、C 3-12环烷基、C 3-12环烷氧基、3-12元杂环基、3-12元杂环氧基、C 5-10芳基、C 5-10芳氧基、5-10元杂芳基、5-10元杂芳氧基和-NR 13R 14的取代基所取代;每个R 12各自独立地选自氢、氘、羟基、C 1-10烷基、C 1-10烷氧基、C 2-10链烯基、C 2-10链炔基、C 3-12环烷基、C 3-12环烷氧基、3-12元杂环基、3-12元杂环氧基、C 5-10芳基、C 5-10芳氧基、 5-10元杂芳基、5-10元杂芳氧基和-NR 13R 14,上述基团任选进一步被一个或多个选自氘、卤素、羟基、氰基、C 1-10烷基、C 1-10烷氧基、C 3-12环烷基、C 3-12环烷氧基、3-12元杂环基、3-12元杂环氧基、C 5-10芳基、C 5-10芳氧基、5-10元杂芳基、5-10元杂芳氧基和-NR 13R 14的取代基所取代;每个R 13和R 14各自独立地选自氢、氘、羟基、C 1-10烷基、C 2-10链烯基、C 2-10链炔基、C 3-12环烷基、3-12元杂环基、C 5-10芳基、5-10元杂芳基、磺酰基、甲磺酰基、异丙磺酰基、环丙基磺酰基、对甲苯磺酰基、氨基、C 1-8烷基单取代氨基、C 1-8烷基二取代氨基和C 1-10烷酰基,上述基团任选进一步被一个或多个选自氘、卤素、羟基、C 1-8烷基、C 1-10烷氧基、C 3-12环烷基、C 3-12环烷氧基、3-12元杂环基、3-12元杂环氧基、C 5-10芳基、C 5-10芳氧基、5-10元杂芳基、5-10元杂芳氧基、氨基、C 1-8烷基单取代氨基、C 1-8烷基二取代氨基和C 1-10烷酰基的取代基所取代;或者,R 13、R 14与其直接相连的氮原子一起形成4-12元杂环基,上述4-12元杂环基任选进一步被一个或多个选自氘、卤素、羟基、C 1-10烷基、C 1-10烷氧基、C 3-12环烷基、C 3-12环烷氧基、3-12元杂环基、3-12元杂环氧基、C 5-10芳基、C 5-10芳氧基、5-10元杂芳基、5-10元杂芳氧基、氨基、C 1-8烷基单取代氨基、C 1-8烷基二取代氨基和C 1-10烷酰基的取代基所取代;每个r各自独立地为0、1或2。
- 根据权利要求1所述的式(I)化合物、其立体异构体或其药学上可接受盐,其特征在于,R 3和R 4各自独立地选自氢、氘、卤素、氰基、C 1-4烷基、C 2-4链烯基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、C 5-8芳基、5-8元杂芳基、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12,或者,R 3和R 4与其直接相连的碳原子一起形成C(O)、3-6元环烷基或3-6元杂环基,上述基团任选进一步被一个或多个选自氘、卤素、氰基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 2-4链烯基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、C 5-8芳基、5-8元杂芳基、=O、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12的取代基所取代;R 5和R 6各自独立地选自氢、氘、卤素、氰基、C 1-4烷基、C 2-4链烯基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、C 5-8芳基、5-8元杂芳基、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12,或者,R 5和R 6与其直接相连的碳原子一起形成C(O)、3-6元环烷基或3-6元杂环基,上述基团任选进一步被一个或多个选自氘、卤素、氰基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 2-4链烯基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、C 5-8芳基、5-8元杂芳基、=O、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12的取代基所取代;条件是R 3、R 4、R 5和R 6不同时为氢;或者,R 4和R 5与其直接相连的部分一起形成3-6元环烷基或3-6元杂环基,上述3-6元环烷基或3-6元杂环基任选进一步被一个或多个选自氘、卤素、氰基、硝基、叠氮基、C 1-4 烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 2-4链烯基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、C 5-8芳基、5-8元杂芳基、=O、-C 0-4烷基-SF 5、-C 0-4烷基-S(O) rR 10、-C 0-4烷基-O-R 11、-C 0-4烷基-C(O)OR 11、-C 0-4烷基-C(O)R 12、-C 0-4烷基-O-C(O)R 12、-C 0-4烷基-NR 13R 14、-C 0-4烷基-C(=NR 13)R 12、-C 0-4烷基-N(R 13)-C(=NR 14)R 12、-C 0-4烷基-C(O)NR 13R 14和-C 0-4烷基-N(R 13)-C(O)R 12的取代基所取代,R 3和R 6如前所定义;其中,R 10、R 11、R 12、R 13、R 14和r如权利要求1所定义。
- 根据权利要求1所述的式(I)化合物、其立体异构体或其药学上可接受盐,其特征在于,R 1选自氢、氘、氟、氯、氰基、羟基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 1-4烷氧基、卤取代C 1-4烷氧基、氘取代C 1-4烷氧基、C 3-6环烷基、4-6元杂环基和-SF 5;R 2a选自氢、氘、氟、氯、氰基、羟基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 1-4烷氧基、卤取代C 1-4烷氧基、氘取代C 1-4烷氧基、C 3-6环烷基、4-6元杂环基和-SF 5;R 2b选自氢、氘、氟、氯、氰基、羟基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 1-4烷氧基、卤取代C 1-4烷氧基、氘取代C 1-4烷氧基、C 3-6环烷基、4-6元杂环基和-SF 5;R 2c选自氢、氘、氟、氯、氰基、羟基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 1-4烷氧基、卤取代C 1-4烷氧基、氘取代C 1-4烷氧基、C 3-6环烷基、4-6元杂环基和-SF 5。
- 根据权利要求1所述的式(I)化合物、其立体异构体或其药学上可接受盐,其特征在于,每个R 7各自独立地选自氢、氘、卤素、氰基、羟基、C 1-4烷氧基、C 1-4烷基、C 2-4链炔基、C 3-6环烷基、4-6元杂环基、-SF 5和氰基取代C 1-4烷基,或者,当m≥2时,两个R 7与其相连的部分一起形成C 3-6环烷基或3-6元杂环基;优选的,每个R 7各自独立地选自氢、氘、氟、氯、氰基、羟基、甲基、乙基、异丙氧基、环丙基、环丁基、环丁氧基、氰甲基和-SF 5。
- 根据权利要求1所述的式(I)化合物、其立体异构体或其药学上可接受盐,其特征在于,R 8和R 9各自独立地选自氢、氘、卤素、氰基、硝基、叠氮基、C 1-4烷基、C 2-4链烯基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、C 5-8芳基、5-8元杂芳基、-C 0-4烷基-SF 5、-C 0-4烷基-S(O) rR 10、-C 0-4烷基-O-R 11、-C 0-4烷基-C(O)OR 11、-C 0-4烷基-C(O)R 12、-C 0-4烷基-O-C(O)R 12、-C 0-4烷基-NR 13R 14、-C 0-4烷基-C(=NR 13)R 12、-C 0-4烷基-N(R 13)-C(=NR 14)R 12、-C 0-4烷基-C(O)NR 13R 14和-C 0-4烷基-N(R 13)-C(O)R 12,上述基团任选进一步被一个或多个选自氘、卤素、氰基、硝基、叠氮基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 2-4链烯基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、C 5-8芳基、5-8元杂芳基、=O、-C 0-4烷基-SF 5、-C 0-4烷基-S(O) rR 10、-C 0-4烷基-O-R 11、-C 0-4烷基-C(O)OR 11、-C 0-4烷基-C(O)R 12、-C 0-4烷基-O-C(O)R 12、-C 0-4烷基-NR 13R 14、-C 0-4烷基-C(=NR 13)R 12、-C 0-4烷基-N(R 13)-C(=NR 14)R 12、-C 0-4烷基-C(O)NR 13R 14和-C 0-4烷基-N(R 13)-C(O)R 12的取代基所取代;优选的,R 8和R 9各自独立地选自氢、氘、卤素、氰基、C 1-4烷基、C 2-4链烯基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、C 5-8芳基、5-8元杂芳基、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、 -C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12,上述基团任选进一步被一个或多个选自氘、卤素、氰基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 2-4链烯基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、C 5-8芳基、5-8元杂芳基、=O、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12的取代基所取代;其中,R 10、R 11、R 12、R 13、R 14和r如权利要求1所定义。
- 根据权利要求1所述的式(I)化合物、其立体异构体或其药学上可接受盐,其特征在于,式(I)化合物具有如下式(Ⅱ)化合物结构:其中,X为CH或N;R 1选自氢、氘、氟、氯、氰基、羟基、甲基、乙基、异丙基、三氟甲基、二氟甲基、三氘甲基、二氘甲基、甲氧基、乙氧基、异丙氧基、三氟甲氧基、二氟甲氧基、三氘甲氧基、二氘甲氧基、三氟异丙氧基、三氘异丙氧基、环丙基、环丁基和环丁氧基;R 2a选自氢、氘、氟、氯、氰基、羟基、甲基、乙基、异丙基、三氟甲基、二氟甲基、三氘甲基、二氘甲基、甲氧基、乙氧基、异丙氧基、三氟甲氧基、二氟甲氧基、三氘甲氧基、二氘甲氧基、三氟异丙氧基、三氘异丙氧基、环丙基、环丁基和环丁氧基;R 2b选自氢、氘、氟、氯、氰基、羟基、甲基、乙基、异丙基、三氟甲基、二氟甲基、三氘甲基、二氘甲基、甲氧基、乙氧基、异丙氧基、三氟甲氧基、二氟甲氧基、三氘甲氧基、二氘甲氧基、三氟异丙氧基、三氘异丙氧基、环丙基、环丁基和环丁氧基;R 3和R 4各自独立地选自氢、氘、-O-R 11和-O-C(O)R 12,或者,R 3和R 4与其直接相连的碳原子一起形成C(O)、3-6元环烷基或3-6元杂环基,上述基团任选进一步被一个或多个选自氘、卤素、氰基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、=O、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12的取代基所取代;R 5和R 6各自独立地选自氢、氘、-O-R 11和-O-C(O)R 12,或者,R 5和R 6与其直接相连的碳原子一起形成C(O)、3-6元环烷基或3-6元杂环基,上述基团任选进一步被一个或多个选 自氘、卤素、氰基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、=O、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12的取代基所取代;条件是R 3、R 4、R 5和R 6不同时为氢;或者,R 4和R 5与其直接相连的部分一起形成3-6元环烷基或3-6元杂环基,上述3-6元环烷基或3-6元杂环基任选进一步被一个或多个选自氘、卤素、氰基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、=O、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-C 0-2烷基-NR 13R 14、-C(=NR 13)R 12、-N(R 13)-C(=NR 14)R 12、-C(O)NR 13R 14和-N(R 13)-C(O)R 12的取代基所取代,R 3和R 6如前所定义;R 7a选自氢、氘、氟、氯、氰基、羟基、甲基、乙基、异丙氧基、环丙基、环丁基和环丁氧基;R 7b选自氢、氘、氟、氯、氰基、羟基、甲基、乙基、异丙氧基、环丙基、环丁基和环丁氧基;R 8选自氢、氘、甲基、乙基、丙基、异丙基、三氟甲基、二氟甲基、三氘甲基、二氘甲基、环丙基、环丁基、氮杂环丁基、氧杂环丁基、甲氧基、乙氧基和异丙氧基;其中,R 10、R 11、R 12、R 13、R 14和r如权利要求1所定义。
- 根据权利要求7所述的式(I)化合物、其立体异构体或其药学上可接受盐,其特征在于,R 5选自-O-R 11和-O-C(O)R 12,上述基团任选进一步被一个或多个选自氘、卤素、氰基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、=O、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(O)NR 13R 14和 -N(R 13)-C(O)R 12的取代基所取代;R 6选自氢和氘;R 3选自氢、氘、-O-R 11和-O-C(O)R 12,R 4选自氢和氘,或者,R 3和R 4与其直接相连的碳原子一起形成C(O)、3-6元环烷基或3-6元杂环基,上述基团任选进一步被一个或多个选自氘、卤素、氰基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、=O、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(O)NR 13R 14和-N(R 13)-C(O)R 12的取代基所取代;其中,R 10、R 11、R 12、R 13、R 14和r如权利要求7所定义。
- 根据权利要求7所述的式(I)化合物、其立体异构体或其药学上可接受盐,其特征在于,R 5和R 6与其直接相连的碳原子一起形成C(O);R 3选自氢、氘、-O-R 11和-O-C(O)R 12,R 4选自氢和氘,或者,R 3和R 4与其直接相连的碳原子一起形成C(O)、3-6元环烷基或3-6元杂环基,上述基团任选进一步被一个或多个选自氘、卤素、氰基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、=O、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-NR 13R 14、-C(O)NR 13R 14和-N(R 13)-C(O)R 12的取代基所取代;其中,R 10、R 11、R 12、R 13、R 14和r如权利要求7所定义。
- 根据权利要求7所述的式(I)化合物、其立体异构体或其药学上可接受盐,其特征在于,R 4和R 5与其直接相连的部分一起形成3-6元环烷基或3-6元杂环基,上述3-6元环烷基或3-6元杂环基任选进一步被一个或多个选自氘、氟、氯、氰基、C 1-4烷基、卤取代C 1-4烷基、氘取代C 1-4烷基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、=O、-SF 5、-S(O) rR 10、-O-R 11、-C(O)OR 11、-C(O)R 12、-O-C(O)R 12、-CH 2-NR 13R 14、-C(O)NR 13R 14和-N(R 13)-C(O)R 12的取代基所取代;R 3选自氢和氘;R 6选自氢和氘;其中,R 10、R 11、R 12、R 13、R 14和r如权利要求7所定义。
- 根据权利要求1所述的式(I)化合物、其立体异构体或其药学上可接受盐,其特征在于,每个R 10各自独立地选自氢、氘、羟基、C 1-4烷基、C 2-4链烯基、C 3-6环烷基、3-6元杂环基、C 5-8芳基、5-8元杂芳基和-NR 13R 14,上述基团任选进一步被一个或多个选自氘、卤素、羟基、氧代、氰基、C 1-4烷基、C 1-4烷氧基、C 3-6环烷基、C 3-6环烷氧基、3-6元杂环基、3-6元杂环氧基、C 5-8芳基、C 5-8芳氧基、5-8元杂芳基、5-8元杂芳氧基和-NR 13R 14的取代基所取代;每个R 11各自独立地选自氢、氘、C 1-4烷基、C 2-4链烯基、C 3-6环烷基、3-6元杂环基、C 5-8芳基和5-8元杂芳基,上述基团任选进一步被一个或多个选自氘、卤素、羟基、氧代、氰基、C 1-4烷基、C 1-4烷氧基、C 3-6环烷基、C 3-6环烷氧基、3-6元杂环基、3-6元杂环氧基、C 5-8芳基、C 5-8芳氧基、5-8元杂芳基、5-8元杂芳氧基和-NR 13R 14的取代基所取代;每个R 12各自独立地选自氢、氘、羟基、C 1-4烷基、C 1-4烷氧基、C 2-4链烯基、C 2-4链炔基、C 3-6环烷基、C 3-6环烷氧基、3-6元杂环基、3-6元杂环氧基、C 5-8芳基、C 5-8芳氧基、5-8元杂芳基、5-8元杂芳氧基和-NR 13R 14,上述基团任选进一步被一个或多个选自氘、卤素、羟基、氰基、C 1-4烷基、C 1-4烷氧基、C 3-6环烷基、C 3-6环烷氧基、3-6元杂环基、3-6元杂环氧基、C 5-8芳基、C 5-8芳氧基、5-8元杂芳基、5-8元杂芳氧基和-NR 13R 14的取代基所取代;每个R 13和R 14各自独立地选自氢、氘、羟基、C 1-4烷基、C 2-4链烯基、C 2-4链炔基、C 3-6环烷基、3-6元杂环基、C 5-8芳基、5-8元杂芳基、磺酰基、甲磺酰基、异丙磺酰基、环丙基磺酰基、对甲苯磺酰基、氨基、C 1-4烷基单取代氨基、C 1-4烷基二取代氨基和C 1-4烷酰基,上述基团任选进一步被一个或多个选自氘、卤素、羟基、C 1-4烷基、C 1-4烷氧基、C 3-6环烷基、C 3-6环烷氧基、3-6元杂环基、3-6元杂环氧基、C 5-8芳基、C 5-8芳氧基、5-8元杂芳基、5-8元杂芳氧基、氨基、C 1-4烷基单取代氨基、C 1-4烷基二取代氨基和C 1-4烷酰基的取代基所取代;或者,R 13、R 14与其直接相连的氮原子一起形成4-6元杂环基,上述4-6元杂环基任选进一步被一个或多个选自氘、卤素、羟基、C 1-4烷基、C 1-4烷氧基、C 3-6环烷基、C 3-6环烷氧基、3-6元杂环基、3-6元杂环氧基、C 5-8芳基、C 5-8芳氧基、5-8元杂芳基、5-8元杂芳氧基、氨基、C 1-4烷基单取代氨基、C 1-4烷基二取代氨基和C 1-4烷酰基的取代基所取代。
- 一种药物组合物,其包括权利要求1-15任一项所述的式(I)化合物、其立体异构体或其药学上可接受盐及可药用的载体。
- 一种权利要求1-15任一项所述的式(I)化合物、其立体异构体或其药学上可接受盐在制备治疗至少部分由K-RAS G12C突变介导的肿瘤或癌症药物中的用途。
- 根据权利要求18所述的用途,其特征在于,所述的癌症或肿瘤选自肺部恶性肿瘤或癌症、肝胆恶性肿瘤或癌症、胃肠道恶性肿瘤或癌症、血液系统恶性肿瘤或癌症、肉瘤、皮肤恶性肿瘤或癌症、骨恶性肿瘤或癌症、泌尿生殖道恶性肿瘤或癌症、神经系统恶性肿瘤或癌症、妇科性恶性肿瘤或癌症和肾上腺恶性肿瘤或癌症。
- 根据权利要求19所述的用途,其特征在于,所述肺部恶性肿瘤或癌症选自支气管癌(鳞状细胞癌、未分化的小细胞、未分化的大细胞或腺癌)、非小细胞肺癌、支气管癌、支气管腺瘤、肉瘤、淋巴瘤、软骨性错构瘤或间皮瘤;所述肝胆恶性肿瘤或癌症选自肝癌、胆管癌、肝母细胞瘤、血管肉瘤、肝细胞腺瘤、血管瘤、胆囊癌、壶腹癌或胆管癌;所述胃肠道恶性肿瘤或癌症选自食道恶性肿瘤和癌症(鳞状细胞癌、腺癌、平滑肌肉瘤或淋巴瘤)、胃恶性肿瘤和癌症(癌、淋巴瘤或平滑肌肉瘤)、胰腺恶性肿瘤和癌症(导管腺癌、胰岛素瘤、胰高血糖素瘤、胃泌素瘤、类癌瘤、葡萄膜瘤)、小肠(腺癌、淋巴瘤、类癌、卡波西氏肉瘤、平滑肌瘤、血管瘤、脂肪瘤、神经纤维瘤、纤维瘤)、大肠癌恶性肿瘤或癌症(腺癌、腺瘤、腺瘤、管状腺瘤)或平滑肌瘤;所述血液系统恶性肿瘤或癌症选自急性或慢性骨髓白血病、急性淋巴细胞白血病、慢性淋巴细胞性白血病、骨髓增生性疾病、多发性骨髓瘤、骨髓增生异常综合症、霍奇金病或非霍奇金淋巴瘤;所述肉瘤选自血管肉瘤、纤维肉瘤、横纹肌肉瘤、脂肪肉瘤、粘液瘤、横纹肌瘤、纤维瘤、脂肪瘤或畸胎瘤;所述皮肤恶性肿瘤或癌症选自恶性黑色素瘤、基底细胞癌、鳞状细胞癌、卡波济肉瘤、痣痣、增生痣、脂肪瘤、血管瘤、皮肤纤维瘤、瘢痕瘤或牛皮癣;所述骨恶性肿瘤或癌症选自成骨肉瘤、纤维肉瘤、恶性纤维组织细胞瘤、软骨肉瘤、尤因氏肉瘤、恶性淋巴瘤、多发性骨髓瘤、恶性巨细胞瘤脊索瘤、骨软骨瘤、良性软骨瘤、软骨母细胞瘤、软骨粘膜纤维瘤、类骨质骨瘤或巨细胞瘤;所述泌尿生殖道恶性肿瘤或癌症选自肾脏恶性肿瘤或癌症(腺癌、威尔姆氏肿瘤或肾母细胞瘤)、淋巴瘤、白血病、膀胱或尿道恶性肿瘤或癌症(鳞状细胞癌、移行细胞癌或腺癌)、前列腺恶性肿瘤或癌症(腺癌或肉瘤)、睾丸恶性肿瘤或癌症(血癌、畸胎瘤、胚胎癌或畸胎瘤)、绒癌、肉瘤、间质细胞癌、纤维瘤、纤维腺瘤、腺瘤样瘤或脂肪瘤;所述神经系统恶性肿瘤或癌症选自骨瘤、血管瘤、肉芽肿、黄瘤、变形性骨炎、脑膜瘤、脑膜肉瘤、胶质瘤病、星形细胞瘤、髓母细胞瘤、神经胶质瘤、室管膜瘤、生殖器瘤、多形胶质母细胞瘤、少突胶质细胞瘤、神经鞘瘤、视网膜母细胞瘤、先天性肿瘤、脊髓神经纤维瘤、脑膜瘤、神经胶质瘤或肉瘤;所述妇科性恶性肿瘤或癌症选自子宫内膜癌(浆液性囊腺癌、粘液性囊腺癌或未分类癌)、颗粒-鞘细胞瘤、睾丸间质细胞瘤、肌膜异常瘤、恶性畸胎瘤、鳞状上皮癌、纤维上皮癌、腺上皮癌、黑色素瘤、透明细胞癌、鳞状细胞癌、葡萄状肉瘤或输卵管癌;所述肾上腺恶性肿瘤或癌症选自神经母细胞瘤。
- 权利要求1-15任一项所述的式(I)化合物、其立体异构体或其药学上可接受盐,其用作治疗至少部分由K-RAS G12C突变介导的肿瘤或癌症的药物。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/267,664 US20240101573A1 (en) | 2020-12-21 | 2021-10-18 | Macrocyclic k-ras g12c inhibitor, preparation method therefor and use thereof |
CA3196367A CA3196367A1 (en) | 2020-12-21 | 2021-10-18 | Macrocyclic k-ras g12c inhibitor, preparation method therefor and use thereof |
JP2023537353A JP2023554476A (ja) | 2020-12-21 | 2021-10-18 | 大環状k-ras g12c阻害剤、その製造方法および使用 |
EP21908774.9A EP4265610A1 (en) | 2020-12-21 | 2021-10-18 | Macrocyclic k-ras g12c inhibitor, preparation method therefor and use thereof |
KR1020237016769A KR20230088804A (ko) | 2020-12-21 | 2021-10-18 | 마크로시클릭 k-ras g12c 억제제, 이의 제조 방법 및 용도 |
AU2021407827A AU2021407827B2 (en) | 2020-12-21 | 2021-10-18 | Macrocyclic k-ras g12c inhibitor, preparation method therefor and use thereof |
CN202180065020.5A CN116249703A (zh) | 2020-12-21 | 2021-10-18 | 一种大环k-ras g12c抑制剂,其制备方法和用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011518497.8 | 2020-12-21 | ||
CN202011518497 | 2020-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022134773A1 true WO2022134773A1 (zh) | 2022-06-30 |
Family
ID=82158760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/124469 WO2022134773A1 (zh) | 2020-12-21 | 2021-10-18 | 一种大环k-ras g12c抑制剂,其制备方法和用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240101573A1 (zh) |
EP (1) | EP4265610A1 (zh) |
JP (1) | JP2023554476A (zh) |
KR (1) | KR20230088804A (zh) |
CN (1) | CN116249703A (zh) |
AU (1) | AU2021407827B2 (zh) |
CA (1) | CA3196367A1 (zh) |
TW (1) | TW202225169A (zh) |
WO (1) | WO2022134773A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020050890A2 (en) * | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
WO2020259513A1 (en) * | 2019-06-24 | 2020-12-30 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of kras g12c |
WO2021086833A1 (en) * | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
WO2021147965A1 (zh) * | 2020-01-21 | 2021-07-29 | 南京明德新药研发有限公司 | 作为kras抑制剂的大环类化合物 |
CN113248521A (zh) * | 2020-02-11 | 2021-08-13 | 上海和誉生物医药科技有限公司 | 一种k-ras g12c抑制剂及其制备方法和应用 |
-
2021
- 2021-10-18 CN CN202180065020.5A patent/CN116249703A/zh active Pending
- 2021-10-18 EP EP21908774.9A patent/EP4265610A1/en active Pending
- 2021-10-18 AU AU2021407827A patent/AU2021407827B2/en active Active
- 2021-10-18 WO PCT/CN2021/124469 patent/WO2022134773A1/zh active Application Filing
- 2021-10-18 JP JP2023537353A patent/JP2023554476A/ja active Pending
- 2021-10-18 CA CA3196367A patent/CA3196367A1/en active Pending
- 2021-10-18 KR KR1020237016769A patent/KR20230088804A/ko active Search and Examination
- 2021-10-18 US US18/267,664 patent/US20240101573A1/en active Pending
- 2021-12-06 TW TW110145415A patent/TW202225169A/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020050890A2 (en) * | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
WO2020259513A1 (en) * | 2019-06-24 | 2020-12-30 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of kras g12c |
WO2021086833A1 (en) * | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
WO2021147965A1 (zh) * | 2020-01-21 | 2021-07-29 | 南京明德新药研发有限公司 | 作为kras抑制剂的大环类化合物 |
CN113248521A (zh) * | 2020-02-11 | 2021-08-13 | 上海和誉生物医药科技有限公司 | 一种k-ras g12c抑制剂及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
AU2021407827A9 (en) | 2024-02-08 |
AU2021407827B2 (en) | 2023-12-21 |
CA3196367A1 (en) | 2022-06-30 |
KR20230088804A (ko) | 2023-06-20 |
AU2021407827A1 (en) | 2023-05-11 |
CN116249703A (zh) | 2023-06-09 |
CN116249703A8 (zh) | 2024-05-31 |
US20240101573A1 (en) | 2024-03-28 |
EP4265610A1 (en) | 2023-10-25 |
JP2023554476A (ja) | 2023-12-27 |
TW202225169A (zh) | 2022-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7311228B2 (ja) | Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 | |
KR102027602B1 (ko) | 신규 화합물 | |
KR102086871B1 (ko) | Fgfr 키나제의 억제를 통한 항암 벤조피라진 | |
KR102072869B1 (ko) | Fgfr 키나제 조절제로서의 퀴놀린 | |
CN112552294B (zh) | 含哌嗪杂环类衍生物抑制剂、其制备方法和应用 | |
TW202043212A (zh) | Shp2抑制劑及其應用 | |
WO2021218110A1 (zh) | 一类苯并噻唑基联芳基类化合物、制备方法和用途 | |
WO2019037678A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
CN113248521B (zh) | 一种k-ras g12c抑制剂及其制备方法和应用 | |
KR20150027121A (ko) | 신규 화합물 | |
CA3221317A1 (en) | Substituted fused azines as kras g12d inhibitors | |
WO2023098439A1 (zh) | 一种吡唑衍生物,其制备方法和在药学上的应用 | |
WO2023098426A1 (zh) | 一种7-(萘-1-基)吡啶并[4,3-d]嘧啶衍生物及其制备和应用 | |
TW201111356A (en) | Nitrogen-containing compound and pharmaceutical composition | |
WO2023098425A1 (zh) | 一种kras抑制剂及其制备和在药学上的应用 | |
WO2021249475A1 (zh) | 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用 | |
JP2019515932A (ja) | チロシンキナーゼbcr−abl阻害剤としての新規複素環化合物 | |
EP2928466A1 (en) | Use of maleimide derivatives for preventing and treating leukemia | |
WO2016140501A1 (en) | Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors | |
WO2002002550A1 (fr) | Nouveaux derives pyrazinone | |
EP3012259B1 (en) | Five-membered heterocyclic pyridine compounds and preparation method and use thereof | |
WO2022134773A1 (zh) | 一种大环k-ras g12c抑制剂,其制备方法和用途 | |
AU2020380828A1 (en) | WDR5 inhibitors and modulators | |
WO2022121839A1 (zh) | 吡啶并[2,3-d]嘧啶-2(1H)-酮衍生物及其制备方法和应用 | |
CN114555597A (zh) | 异柠檬酸脱氢酶(idh)抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21908774 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3196367 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021407827 Country of ref document: AU Date of ref document: 20211018 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20237016769 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18267664 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023537353 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021908774 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021908774 Country of ref document: EP Effective date: 20230721 |